Additional High Blood Pressure Drug Recalled Due to NDEA Impurity

Irbesartan, an angiotensin II receptor blocker (ARB), the same class of drug as Valsartan, has been recalled by the FDA due a potential cancer risk. Used as a standalone drug or in conjunction with other medications, Irbesartan is prescribed to treat hypertension (high blood pressure). The drug can also be prescribed to treat high blood pressure with diabetic nephropathy. A complication of type 2 diabetes, diabetic nephropathy can impair kidney function. Like other ARBs the drug works by blocking the action of natural substances that constrict blood vessels, allowing the heart to work more efficiently and blood to flow more smoothly.

We’re Here To Help.

Free, No Obligation Irbesartan Consultation.

Known Carcinogen N-Nitrosodiethlamine (NDEA) Found in Irbesartan

Often associated with industrial processes, NDEA is a synthetic light-sensitive, volatile, clear yellow oil that is soluble in water, lipids and other organic solvents. It may be used as an additive in lubricants, as a gasoline and/or a stabilizer for industry materials. It is also used in experimental research to induce liver tumorigenesis. NDEA has been classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC).

Nationwide Recall of Hypertension Drug Irbesartan

Sciegen Pharmaceuticals, Inc. has issued a voluntary nationwide recall of Irbesartan tablets, USP 75 mg, 150 mg, and 300 mg due to the potential cancer risk related to the NDEA impurity. The October 2018 recall affects multiple batches of the drug, supplied by Aurobindo Pharam Limited, headquartered in India. The recalled ScieGen Pharmaceuticals Inc. Irbesartan was labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc., a list of the recalled lot numbers is included in the recall.

Long-term exposure to NDEA may increase the risk of digestive system cancers as it is known to target the liver, esophagus and stomach in animals.

Irbesartan Related Injuries

Exposure to N-Nitrosodiethlamine (NDEA) may cause cancer. Injuries from NDEA exposure include but are not limited to:

  • Liver Cancer
  • Kidney Cancer
  • Colorectal Cancer
  • Intestinal cancer
  • Stomach Cancer
  • Bladder Cancer
  • Liver Damage Requiring Hospitalization

Get Irbesartan Recall Help Today.

If you have been taking the HBP medication Irbesartan contaminated with NDEA and are suffering from liver, kidney, or other digestive cancers, you may be entitled to compensation. Click, Chat or call 1800LAW1010 24/7 for a free case evaluation.